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Abstract: Cardiovascular disease is the major cause of mortality worldwide and accounts for 
approximately 40% of all deaths. Dyslipidemia is one of the primary causes of atherosclerosis 
and effective interventions to correct dyslipidemia should form an integral component of 
any strategy aimed at preventing cardiovascular disease. Fibrates have played a major role 
in the treatment of hyperlipidemia for more than two decades. Fenofibrate is one of the most 
commonly used fibrates worldwide. Since fenofibrate was first introduced in clinical practice, 
a major drawback has been its low bioavailability when taken under fasting conditions. 
Insoluble Drug Delivery-Microparticle fenofibrate is a new formulation that has an equivalent 
extent of absorption under fed or fasting conditions. In this review, we will discuss the clinical 
pharmacology of fenofibrate, with particular emphasis on this novel formulation, as well as its 
lipid-modulating and pleiotropic actions. We will also analyze the major trial that evaluated 
fibrates for primary and secondary prevention of cardiovascular disease, the safety and efficacy 
profile of fibrate–statin combination treatment, and the current recommendations regarding the 
use of fibrates in clinical practice.
Keywords: fibrates, fenofibrate, combination treatment, dyslipidemia, cardiovascular disease, 
pleiotropic actions
Introduction
Cardiovascular disease (CVD) is the major cause of mortality worldwide and accounts 
for approximately 40% of all deaths (AHA 2001). In the US alone, nearly 1 million 
individuals die of CVD each year whereas 25% of the adult population (62 million) 
has CVD (AHA 2001). The existing burden of CVD will continue to increase in 
developed countries as the population ages. Dyslipidemia is one of the primary 
causes of atherosclerosis and CVD, and effective interventions to correct dyslipidemia 
should form an integral component of any strategy aimed at preventing CVD (NCEP 
2002).
Fibrates have played a major role in the treatment of hyperlipidemia for more than 
two decades (Miller and Spence 1998). The first member of this class, clofibrate, was 
identified in 1962 by Thorp and Waring (1962) and became available in the US in 
1967. Many other fibrates, including ciprofibrate, bezafibrate, etofibrate, beclofibrate, 
and pirifibrate, are available in Europe, where the use of such agents is more extensive 
(Miller and Spence 1998; Guay 1999). The third-generation fibric acid derivative 
fenofibrate was synthesized in 1975 (Keating and Ormrod 2002) and was introduced 
into clinical practice in France the same year (Blane 1989; Keating and Ormrod 2002). 
The original generic name procetofene was changed to fenofibrate to comply with World 
Health Organization nomenclature guidelines. Fenofibrate is marketed in 86 countries 
and is one of the most commonly used fibrates worldwide, with more than 6 million 
patient-years of experience (Brown 1988). More than 80 clinical trials of fenofibrate 
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have involved more than 9000 patients and more than 
31 000 patient-years of drug exposure (Blane 1989; Keech 
et al 2005). Its indications include hypercholesterolemia, 
combined dyslipidemia, remnant hyperlipidemia, endo-
genous hyperlipemia (hypertriglyceridemia), and mixed 
hyperlipemia (Frederickson types IIa, IIb, III, IV, and V 
dyslipidemia, respectively) (Keating and Ormrod 2002).
In this review, we will discuss the clinical pharmacology   
of fenofibrate, with particular emphasis on its novel 
formulation (Triglide™), as well as its lipid-modulating 
and pleiotropic actions. We will also analyze the major trial 
that evaluated fibrates for primary and secondary prevention 
of CVD, the safety and efficacy profile of fibrate–statin 
combination treatment and the current recommendations 
regarding the use of fibrates in clinical practice.
Clinical pharmacology
Chemically, fenofibrate is 2-(4[4-chlorobenzoyl]phenoxy)-
2-methyl-propanoic acid, 1-methylethyl ester. Fenofibrate 
is a poorly soluble ester of its active derivative, fenofibric 
acid (Chapman 1987; Adkins and Faulds 1997; Miller 
and Spence 1998; Munoz et al 1999; Guichard et al 2000; 
Keating and Ormrod 2002; Ramjattan et al 2002). After oral 
administration, it is rapidly converted through hydrolysis of 
its ester bond to fenofibric acid (Adkins and Faulds 1997; 
Miller and Spence 1998; Munoz et al 1999; Guichard et al 
2000; Streel et al 2000; Keating and Ormrod 2002; Ramjattan 
et al 2002). Hydrolysis is catalyzed by both tissue and plasma 
esterases and appears to commence concomitantly with 
absorption (Chapman 1987). No unmodified fenofibrate is 
found in human plasma (Chapman 1987; Caldwell 1989; 
Adkins and Faulds 1997; Streel et al 2000). Plasma levels 
of fenofibric acid peak 6–8 hours after oral administration 
(Caldwell 1989; Hunninghake 1989; Balfour et al 1990; 
Adkins and Faulds 1997). Steady-state plasma levels are 
reached within 5 days of dosing, and no accumulation has 
been observed in healthy volunteers after administration 
of multiple doses. Fenofibric acid is extensively protein-
bound (99%), primarily to albumin, and has an apparent 
volume of distribution of 0.89 L/kg (Balfour et al 1990; 
Adkins and Faulds 1997). Fenofibric acid is metabolized 
by the hepatic cytochrome P (CYP)-450 3A4 isozyme 
and has a half-life of 20 hours, which allows once-daily 
administration (Desager and Harvengt 1978; Miller and 
Spence 1998). Fenofibric acid is mainly (60%) excreted in 
urine as metabolites, primarily fenofibric acid and fenofibric 
acid glucuronide; 25% is eliminated in feces (Desager et 
al 1982). Fenofibric acid accumulates with chronic use in 
patients with mild to severe chronic renal disease; the plasma 
half-life of fenofibric acid is prolonged in these patients, but 
does not correlate with creatinine clearance (Balfour et al 
1990). Hemodialysis does not affect the plasma kinetics of 
the drug, as fenofibric acid is virtually nondialyzable from 
plasma (Desager et al 1982).
Since fenofibrate was first introduced in clinical practice, 
a major drawback has been its low bioavailability when taken 
under fasting conditions, since it is virtually insoluble in water 
and highly lipophilic (Desager and Harvengt 1978; Adkins 
and Faulds 1997; Guay 2002; Keating and Ormrod 2002; 
Najib 2002; Ramjattan et al 2002). In contrast, its absorption 
is substantially increased in the presence of food and, 
particularly, fat (Caldwell 1989; Hunninghake 1989; Balfour 
et al 1990; Adkins and Faulds 1997; Munoz et al 1999). The 
bioavailability of the original formulation of fenofibrate was 
improved through a micronization process, and a micronized 
capsule formulation has been commercially available in the 
US since 1998 (Munoz et al 1999; Abbott Laboratories 2000; 
Guichard et al 2000; Keating and Ormrod 2002; Ramjattan 
et al 2002). Since July 2001, a new tablet formulation of 
fenofibrate has been available that combines micronization 
technology with a microcoating process, allowing more 
predictable and reliable drug absorption (Guichard et al 2000; 
Abbott Laboratories 2001). Nevertheless, product labeling of 
formulations marketed to date has mandated administering 
the drug with meals, even for these two new formulations 
(Adkins and Faulds 1997; Abbott Laboratories 2000, 2001; 
Keating and Ormrod 2002; Ramjattan et al 2002).
In clinical practice, however, patients may confuse the 
fenofibrate dosage regimen with the traditional regimen 
for statins and take fenofibrate at bedtime on an empty 
stomach. Additionally, patients may vary from each other 
and from day to day in their adherence to the low-fat dietary 
guidelines for dyslipidemic individuals (NCEP 2002). Even 
if these guidelines are rigorously followed, they limit the fat 
content of patients’ meals and therefore may compromise the 
bioavailability of currently marketed fenofibrate products. In 
the context of these real-world circumstances, the food and 
fat effects seen with currently marketed products may lead 
to inconsistent, unpredictable, and suboptimal fenofibrate 
bioavailability, which, in turn, jeopardizes clinical efficacy 
(Desager et al 1996).
Insoluble Drug Delivery-Microparticle (IDD-P) 
fenofibrate tablets (TRICOR) are a new formulation 
developed to provide fenofibrate bioavailability independent 
of food and its fat content (Mishra et al 2002). The technology 
used to develop this formulation involves preparing international Journal of Nanomedicine 2006:1(2) 131
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microparticles of drug and stabilizing them with phospholipid 
surface-modifying agents that prevent the microparticles 
from reaggregating (Mishra et al 2002). Thus, this approach 
preserves the expanded drug surface area that results from 
microparticularization (Mishra et al 2002). Exposure of 
the expanded drug surface area to the in vivo dissolution 
medium upon oral administration thereby increases 
bioavailability (Mishra et al 2002). IDD-P fenofibrate 160-
mg tablets have an equivalent extent of absorption under 
fed or fasting conditions, suggesting that dosage regimens 
could include administration of the product without food 
(Guivarc’h et al 2004). In addition, they have comparable 
bioavailability regardless of the fat content of the test meal, 
suggesting that its bioavailability would remain consistent 
regardless of patients’ adherence to low-fat dietary guidelines 
(Guivarc’h et al 2004). Administering a drug independently 
of food may provide greater convenience and simplicity 
for patients and prescribers. Simplicity of administration 
is particularly relevant given the chronic nature of lipid-
lowering therapy, the demands of complying with low-fat 
dietary recommendations, and the complexity of multiple 
treatments for associated conditions.
Fenofibrate potentiates the effects of oral anticoagulants, 
necessitating close monitoring of the international normalized 
ratio and reduction of the warfarin dose by approximately one 
third (Lemaire and Tillement; 1982; Adkins and Faulds 1997; 
Kim and Mancano 2003). The high level of protein binding 
associated with fenofibrate may cause displacement of 
warfarin, but the effect is generally small and concentrations 
of unbound anticoagulant do not change in vivo, leading some 
investigators to reject this as a significant cause of interaction 
(Ascah et al 1998; Guay 1999). Fenofibrate also interacts 
with cyclosporin and there may be a risk of nephrotoxicity, 
severe myositis, and rhabdomyolysis when the two agents are 
co-administered (Boissonnat et al 1994). Many sulfonylureas 
are highly protein bound and may be displaced from albumin 
by fibrates (Ahmad 1991). Hence, patients receiving agents 
from both classes must be monitored for signs and symptoms 
of hypoglycemia. Although there does not appear to be any 
pharmacokinetic interaction between fenofibrate and bile 
acid sequestrants, it is recommended that fenofibrate be given 
more than 1 hour before or 4–6 hours after administration 
of a bile acid-binding resin (First Horizon Pharmaceutical 
Corporation 2005).
Fenofibrate is generally well tolerated. Side-effects 
are primarily gastrointestinal in nature (Keech et al 2005). 
Abnormal liver function tests and increased creatine kinase 
(CK) levels are infrequently reported (Adkins and Faulds 
1997; Guay 1999; Keating and Ormrod 2002; Barker et al 
2003; Kiortsis et al 2003). Only 1 trial reported elevations of 
CK twice the upper limit of normal in 4 bezafibrate-treated 
patients versus 1 placebo-treated patient and it is not clear 
whether these elevations were symptomatic (The BIP study 
group 2000). Post-marketing surveillance of fenofibrate 
found only a 2% discontinuation rate due to adverse events 
(Keating and Ormrod 2002). Fenofibrate has been reported 
to cause similar changes in biliary lipid composition to 
those observed with other fibric acid derivatives (Palmer 
1987). However, fenofibrate may have a lower propensity 
to cause gallstones, as it increases phospholipid content and 
decreases bile acid content, which appears to favor liquid 
crystal formation (Palmer 1987). A nonsignificant excess in 
noncardiovascular disease deaths has been reported in some 
fibrate trials (Heady et al 1992; Keech et al 2005; Studer et al 
2005). However, this apparent excess was not attributable to 
any specific cause of death, nor was it linked to a significant 
increase in any specific nonfatal noncardiovascular disease 
event, such as invasive cancers, and so remains consistent 
with a chance finding (Keech et al 2005). The dose of 
fenofibrate should be reduced in patients with severe renal 
impairment (creatinine clearance < 50 mL/min) and increased 
only after effects on renal function have been evaluated; no 
dose reduction is required in patients with moderate renal 
impairment (creatinine clearance 50–90 mL/min). The use of 
fenofibrate is contraindicated in patients with hypersensitivity 
to this agent, pre-existing gallbladder disease, hepatic 
dysfunction, and unexplained persistent abnormality in liver 
function.
Lipid-modulating actions of 
fenofibrate
Fenofibrate has a wide range of effects on the synthetic and 
catabolic pathways of cholesterol and triglycerides (TG) 
metabolism (Balfour et al 1990; Adkins and Faulds 1997). In 
the 1990s, it was realized that
 the lipid-modifying properties 
of fibrates were attributable
 to the selective activation of 
nuclear transcription factor peroxisome proliferator-activated 
receptor alpha (PPARα) (Gonzalez et al 1998; Knopp 1999). 
PPARα is expressed
 mainly in tissues where active free 
fatty acid (FFA) catabolism occurs
 (liver, skeletal muscle, 
heart, and kidney), as well as in vascular endothelium, 
vascular smooth
 muscle, and macrophage–foam cells 
(Kersten et al 2000). Upon activation by ligand binding in 
the cytoplasm, PPARs migrate to the nucleus where they 
heterodimerise with the retinoic acid X receptor (RXR); these 
PPAR-RXR dimers bind to DNA-specific
 sequences called international Journal of Nanomedicine 2006:1(2) 132
Tziomalos and Athyros
peroxisome proliferator–response elements,
 thus stimulating 
or dampening the transcription of key genes of the lipid 
metabolism (Staels et al 1998; Kersten et al 2000).
Fenofibrate substantially reduces TG by about 30% 
(Keating and Ormrod 2002; Keech et al 2005). TG exert a 
direct effect on the expansion of the lipid-rich core of the 
atherosclerotic plaques (Rubins et al 2002). The bulk of the 
evidence now suggests that an elevated fasting TG level is 
an independent risk factor for coronary heart disease (CHD) 
(de Faire et al 1996; Ruotolo et al 1998). Fibrates exert their 
hypotriglyceridemic action primarily by enhancing hepatic 
catabolism of FFA, which results in reduced production of 
TG-rich very low-density lipoprotein cholesterol (VLDL-C), 
and by inducing hepatic lipoprotein lipase (LPL) expression 
(Schoonjans, Staels, et al 1996; Staels, Dallongeville, et al 
1998; Watts and Dimmitt 1999). Fibrates’ hypotriglyceri-
demic action is further enhanced by PPARα-mediated 
inhibition of apolipoprotein (apo) CIII gene expression; 
apoCIII delays the catabolism of TG-rich lipoproteins, since it 
inhibits their binding to the endothelial surface and lipolysis 
by LPL and interferes with the clearance of remnant particles 
from plasma (Staels et al 1995; Schoonjans, Staels, et al 
1996; Fruchart et al 2001; Barbier et al 2002). Furthermore, 
fenofibrate induces apolipoprotein AV , a recently discovered 
lipoprotein, which results in a significant reduction in serum 
TG (Pennacchio et al 2001; Vu-Dac et al 2003).
Fenofibrate consistently raises high-density lipoprotein 
cholesterol (HDL-C) in the range of 5%–50%, depending 
on lipid phenotype and baseline concentration, with the 
greatest elevations being observed when baseline HDL-C is 
less than 1.03 mmol/L (Shepherd et al 1985; Schonfeld 1994; 
Guerin et al 1996; Adkins and Faulds 1997; Kirschgassler et 
al 1998; Poulter 1999; le Roux et al 2002; Keech et al 2005). 
HDL-C protects against atherosclerosis primarily by carrying 
cholesterol away from blood vessel walls to the liver, where 
it is metabolized (reverse cholesterol transport). In addition, 
HDL-C displays antioxidant, anti-inflammatory, and plaque-
stabilizing properties (Von Eckardstein et al 2001; Sacks 
2002, 2003). Decreased HDL-C is a potent and independent 
risk factor for CHD; both observational studies and controlled 
clinical trials suggest that each 1% increase in HDL-C is 
associated with a 2%–3% reduction in risk of CHD (Miller et 
al 1977; Goldbourt et al 1979; Wilson et al 1988; Gordon et al 
1989; Gordon and Rifkind 1989; Jacobs et al 1990; Assmann 
et al 1996; Fruchart et al 1998; Boden 2000; Sacks et al 2000; 
NCEP 2002; Sacks 2002, 2003; Athyros et al 2004a). Fibrates 
increase HDL-C by decreasing VLDL-C concentrations, 
which causes a decreased transfer of cholesterol from HDL-
C to VLDL-C (Grundy and Vega 1987; Hunninghake and 
Peters 1987). HDL levels are equally increased with fibrates 
via promotion of the synthesis and production of apoA-I and 
apoA-II, which are the major protein constituents of HDL-C 
and are integral to the process of reverse cholesterol transport 
(Knopp et al 1987; Hunninghake 1989; Adkins and Faulds 
1997; Staels, Dallongeville, et al 1998; Watts and Dimmitt 
1999; Chinetti et al 2001).
In hypertriglyceridemic dyslipidemias, lipid-poor, small 
HDL-C particles with attenuated antiatherogenic activities 
are preferentially formed (Lamarche et al 1999). Fibrates 
shift this HDL-C profile towards large, cholesteryl ester-rich 
particles, which are more potent in withdrawing cholesterol 
from peripheral tissues. The underlying mechanism is the 
fibrate-mediated reduction in the numbers of acceptor 
particles (VLDL-C, intermediate-density lipoprotein 
cholesterol [IDL-C], low-density lipoprotein cholesterol 
[LDL-C]) for cholesteryl ester transfer from HDL, which 
results in increased retention of cholesteryl ester in HDL, 
whose particle size increases (Guerin et al 1996; Durrington 
et al 1998; Staels, Dallongeville, et al 1998; Watts and 
Dimmitt 1999; Sasaki et al 2002).
The effects of fibrates on LDL-C are much smaller, and 
somewhat varied – in 2 major fibrate trials, no fall in LDL-C 
was reported with gemfibrozil (Rubins et al 2002) or with 
bezafibrate (The BIP Study Group 2000). An average increase 
of 15% is also not unexpected in patients with baseline TG 
values > 3.4 mmol/L, since fibrates increase conversion of 
VLDL-C to LDL-C through enhanced delipidation (Staels, 
Dallongeville, et al 1998; Westphal et al 2003; Ikewaki et al 
2004). With fenofibrate, a fall of 13% in LDL-C cholesterol 
was noted in a recent landmark study (Keech et al 2005). 
Epidemiological surveys in many populations throughout the 
world have shown a log-linear relationship between LDL-C 
levels and CHD risk over a broad range of cholesterol values 
(Law and Wald 1994; Law et al 1994, 2003). Fenofibrate 
may inhibit hydroxymethyl-glutaryl coenzyme A reductase 
activity, thus reducing cholesterol synthesis, and might 
also increase the clearance of circulating LDL-C via the 
high-affinity receptor system (Haubenwallner et al 1995; 
Schoonjans, Peinado-Onsurbe, et al 1996). Fenofibrate has 
also been reported to increase cholesterol excretion into the 
bile, contributing to lower intracellular cholesterol levels 
and providing added stimulus to the generation of LDL-C 
receptors in the liver (Brown 1988).
Fibrates modify the subgroup pattern of LDL-C from 
small, dense particles to large, buoyant particles; this effect 
is more pronounced with fenofibrate, involving up to 50% international Journal of Nanomedicine 2006:1(2) 133
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reduction in dense LDL-C particles levels (Shepherd et al 
1985; Schonfeld 1994; Auwerx et al 1996; Guerin et al 1996; 
Anber et al 1997; Ruotolo et al 1998; Staels, Dallongeville, 
et al 1998; Feher et al 1999). Dense LDL-C particles are of 
elevated atherogenic potential (de Graaf et al 1991; Tribble 
et al 1992; Chait et al 1993 ; Griffin et al 1994; Anber 
et al 1996; Lamarche et al 1997). They possess a lower 
binding affinity for the LDL receptor than light particles, 
and thus a longer residence time in plasma in vivo (Packard 
and Shepherd 1977; Chapman et al 1998). Dense LDL-C 
particles also exhibit high affinity for binding to arterial 
proteoglycans, leading to their preferential retention at 
sites in the arterial wall of high endothelial permeability, 
as at bifurcations in the arterial tree (Williams and Tabas 
1995; Anber et al 1997). They are, therefore, exposed to 
biological modifications (Chapman et al 1998), which may 
lead to their catabolism by atherogenic pathways, such as 
the macrophage pathway (Young and Parthasarathy 1994). 
Dense LDL-C particles also exhibit diminished resistance to 
oxidative stress in vitro. Oxidized LDL-C particles are avidly 
bound, internalized, and degraded by macrophages, leading 
to their transformation into foam cells, the latter representing 
a key cellular component of atheromatous lesions (Young 
and Parthasarathy 1994). LDL-C particle size has been 
shown to be an independent predictor of the degree of CHD 
progression (Vakkilainen et al 2003).
Fibrates also reduce VLDL-C, VLDL-C remnants, and 
IDL-C in both fasting and postprandial states (Schonfeld 
1994; Rubins et al 1995; Anber et al 1997; Chapman et 
al 1998). Fenofibrate mediates marked decreases, up to 
60%, in the area under the postprandial curve for these 
lipoproteins (Simpson et al 1990; Staels, Dallongeville, et 
al 1998; Cavallero et al 2003; Westphal et al 2003; Ooi et al 
2004). The postprandial phase is of considerable relevance 
to atherogenesis in dyslipidemic subjects and is intimately 
associated with endothelial dysfunction and oxidative stress 
(Simpson et al 1990; Karpe et al 1993; Cohn 1994; Evans et 
al 1999; Kugiyama et al 1999; Kolovou et al 2005). Extensive 
evidence substantiates the atherogenicity and cytotoxicity 
to endothelial cells of VLDL-C and their remnants, which 
represent major risk factors for premature atherosclerotic 
disease (Simpson et al 1990; Karpe et al 1993; Cohn 
1994; Alaupovic et al 1997; Evans et al 1999; Gianturco 
and Bradley 1999; Kugiyama et al 1999). Following 
transendothelial transport, these lipoprotein particles are 
retained in the arterial intima, where they undergo structural 
modification, including oxidation, resulting in macrophage 
uptake (Williams and Tabas 1995). Equally, native VLDL-
C subfractions may directly induce lipid accumulation in 
monocyte-macrophages via LPL-mediated mechanisms 
involving lipolysis and/or ligand binding; macrophage lipid 
accumulation is a key factor in the transformation of these 
cells to a proinflammatory and prothrombogenic phenotype 
(Milosavljevic et al 2001).
Fenofibrate reduces levels of apoB, a major component 
of LDL-C and TG-rich lipoproteins (Gami et al 2003). Few 
studies have reported on the influence of fenofibrate therapy 
on lipoprotein (a) and both an absence of effect (Adkins 
and Faulds 1997; Guay 2002) and a significant decrease 
(Bairaktari et al 1999) have been reported.
The lipid-modulating actions of fibrates are to some 
degree phenotype-dependent, but this question has not been 
systematically addressed (Schonfeld 1994). For example, TG 
lowering is of greatest magnitude in hypertriglyceridemic 
phenotypes and may exceed 50%, but is lower, and typically 
less than 30%, in type IIa hypercholesterolemia (Shepherd 
et al 1985; Schonfeld 1994; Guerin et al 1996; Adkins and 
Faulds 1997; Kirschgassler et al 1998; Rubins et al 1999). 
Equally, the potency of fibrates to lower LDL-C is influenced 
by the initial concentration; in the type IIa phenotype for 
example, LDL-C and apoB reduction typically range up to 
25% (Shepherd et al 1985; Schonfeld 1994; Guerin et al 1996; 
Adkins and Faulds 1997; Kirschgassler et al 1998). In the IIb 
phenotype, LDL-C lowering is comparable with that in type 
IIa, whereas plasma TG and VLDL-C reductions tend to be 
superior (30%–50%) (Shepherd et al 1985; Schonfeld 1994; 
Guerin et al 1996; Adkins and Faulds 1997; Kirschgassler 
et al 1998).
The relative potency of fibrates in lowering levels of 
lipoproteins has not been compared in large, randomized, 
placebo-controlled, crossover trials. The activity of 
fenofibrate in a cell-based transactivation assay for PPARα 
is 40% greater than that of either bezafibrate or clofibrate 
(Willson et al 2000; Chapman 2003). The lipid-lowering 
effects of fenofibrate are 6-fold greater than those achieved 
with an equivalent dose of clofibrate (Blane 1989). It is 
also generally recognized that fenofibrate tends to be more 
efficacious in lowering LDL-C than gemfibrozil in both the 
IIa and IIb phenotypes (Schonfeld 1994). In major clinical 
trials, gemfibrozil induced small decreases in LDL-C levels 
or did not affect them at all (Frick et al 1987, 1997; Rubins 
et al 1999); in fact, in people who have very high TG-rich 
lipoproteins, treatment with gemfibrozil may result in an 
increase in LDL-C (Steiner 2005). Bezafibrate can also 
reduce LDL-C in a range of 10%–20% depending on the 
lipoprotein abnormality, although in the major clinical international Journal of Nanomedicine 2006:1(2) 134
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trials with bezafibrate, no effect on LDL-C concentrations 
was observed (de Faire et al 1996; Elkeles et al 1998; The 
BIP Study Group 2000; Steiner 2005). Finally, ciprofibrate, 
similar to fenofibrate, has been shown to mediate marked 
reduction (up to 60%) in the area under the postprandial curve 
for TG and TG-rich lipoproteins (Evans et al 1999).
Pleiotropic actions of fenofibrate
Results from clinical trials have suggested that the 
cardioprotective effects of fibrate treatment cannot be 
explained solely by changes in the traditional lipid profile, 
suggesting that fibrate-induced modifications of emerging 
risk factors may contribute to their beneficial effects on 
cardiovascular endpoints (Manninen et al 1992; Staels, 
Dallongeville, et al 1998; NICE 2002; Rubins et al 2002; 
Robins et al 2003; Vakkilainen et al 2003; Despres et al 
2004; Ikewaki et al 2004; Tsimihodimos et al 2005). The 
activation of PPARα by fenofibrate regulates the expression 
of key genes involved in all stages of atherogenesis, including 
vascular inflammation, plaque instability, and thrombosis 
and exerts direct antiatherogenic actions in the vascular wall 
(Barbier et al 2002).
Atherosclerosis is a chronic inflammatory disorder with 
an inflammation component in all stages of atherogenic 
plaque formation and growth (Ross 1999). A growing 
number of studies confirms that fibrates act pleiotropically 
on inflammatory processes, and that their efficacy in this field 
is comparable with that of statins (Wang et al 2003). Fibrates 
exert anti-inflammatory action by inhibiting the production 
of inflammatory cytokines, including interleukin (IL) IL-1α, 
IL-1β, IL-2, IL-6, interferon-γ, and tumor necrosis factor-
α; this action results from repression of nuclear factor κb 
transcriptional activity (Staels et al 1995; Madej et al 1998; 
Staels, Koenig, et al 1998; Kleemann et al 2003; Wang et 
al 2003; Okopien et al 2004, 2005; Koh, Ahn, Han, et al 
2004). Fenofibrate therapy significantly lowers C-reactive 
protein (CRP) (Staels, Koenig, et al 1998; Marx et al 1999; 
Barbier et al 2002; Wang et al 2003; Ikewaki et al 2004; 
Tsimihodimos et al 2004; Gervois et al 2004; Athyros et 
al 2005; Koh, Ahn, Han, et al 2005; Undas et al 2005), 
even more than atorvastatin (Malik et al 2001). Prospective 
epidemiological studies have found increased vascular risk 
in association with increased levels of CRP (Kuller et al 
1996; Haverkate et al 1997; Ridker et al 1997, 1998, 2000; 
Tracy et al 1997; Koenig et al 1999). It also lowers the 
CD40 ligand, which plays an important role in a cascade 
of inflammatory and proatherothrombotic functions (Libby 
and Simon 2001; Schönbeck and Libby 2001; Wang et al 
2003; Undas et al 2005). Fenofibrate can also reduce the 
expression of monocyte chemoattractant protein-1, which 
controls chemotaxis of mononuclear cells into the vascular 
wall (Pasceri et al 2001; Kowalski et al 2003; Undas et al 
2005), as well as vascular cell adhesion molecule-1 and 
intercellular adhesion molecule-1 levels (Marx et al 1999; 
Marchesi et al 2003). These anti-inflammatory actions of 
fenofibrate have been reported to occur as early as after 3 days 
of therapy and are independent of changes in lipid profiles 
(Undas et al 2005). Fenofibrate also lowers serum amyloid A 
(Marx et al 1999; Gervois et al 2004). Fenofibrate may also 
exhibit antioxidant activity (Inoue et al 2001), decrease the 
production of reactive oxygen species (Iglarz et al 2003), 
and reduce the concentration of lipid peroxidation products 
(Beltowski et al 2002).
In dyslipidemic patients, a procoagulant state is 
observed, with elevated levels of fibrinogen and plasminogen 
activator inhibitor-1 (PAI-1) (Okopien et al 2001, 2005). 
Many prospective studies have shown that fibrinogen is an 
independent risk factor for CVD (Wilhelmsen et al 1984; 
Stone and Thorp 1985; Meade et al 1986; Kannel et al 1987; 
Yarnell et al 1991; Ernst and Koenig 1997). Fenofibrate 
lowers plasma fibrinogen levels by up to 20%, independently 
of lipid changes (Stokhler et al 1989; Branchi et al 1993; 
Durrington et al 1998; Staels, Koenig, et al 1998; Kockx et al 
1999; Marx et al 1999; Barbier et al 2002; Guay 2002; Maison 
et al 2002; Gervois et al 2004; Koh, Ahn, Han, et al 2004; 
Koh, Han, Quon, 2005; Saklamaz et al 2005), in contrast to 
gemfibrozil, which may induce elevations (Branchi et al 1993; 
Durrington et al 1998; Mussoni et al 2000). This decrease 
in fibrinogen levels is associated with a decrease in plasma 
viscosity and an improvement in red cell aggregation and 
microcirculation (Haak et al 1998; Frost et al 2001). Different 
hypotheses may explain the nonlipid effect of fenofibrate on 
fibrinogen, including the direct suppression of fibrinogen 
gene expression (Kockx et al 1999), the inhibition of IL-6, 
which promotes fibrinogen synthesis in the liver (Green 
and Humphries 1989; Di Minno and Mancini. 1992), or a 
direct action on fibrin gel and thrombus structure (Kockx et 
al 1997, 1998). Fenofibrate also significantly lowers plasma 
concentrations of thrombin-antithrombin complexes (Undas 
et al 2005) and PAI-1 (Durrington et al 1998; Okopien et al 
2001, 2005), and suppresses the upregulation of tissue factor 
expression on stimulated monocytes and macrophages (Marx 
et al 2001; Neve et al 2001).
Evidence exists that fenofibrate can improve nitric 
oxide (NO) bioavailability (Koh, Ahn, Jin, et al 2004) and 
endothelial
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phase, and independently of changes in plasma lipids (Liang 
et al 2000; Malik et al 2001; Sebestjen et al 2002; Capell 
et al 2003; Marchesi et al 2003; Playford et al 2003; Wang 
et al 2003; Koh, Ahn, Han, et al 2004; Koh, Han, Quon, et 
al 2005). Fenofibrate may also prevent the development of 
angiotensin II-dependent hypertension (Diep et al 2002; Vera 
et al 2005), as well as myocardial inflammation and fibrosis 
(Diep et al 2004; Ogata et al 2004). Some, but not all, studies 
suggest that the fibrate-induced improvement in serum lipids 
is followed by a decrease in blood pressure (Walus-Idzior et 
al 2000; Keech et al 2005).
Among fibrates, only fenofibrate significantly decreases 
serum uric acid (Elisaf et al 1999; Elisaf 2002; Liamis et 
al 1999; Kiortsis and Elisaf 2001; Achimastos et al 2002). 
Uric acid levels are probably related to adverse outcomes 
in patients with CHD (Fang and Alderman 2000; Bickel et 
al 2002; Athyros, Elisaf, et al 2004). Furthermore, a recent 
prospective cohort study of 1423 middle-aged men without 
CVD or type 2 diabetes mellitus (DM) at baseline, found 
uric acid to be an independent and strong predictor of CVD 
mortality (Niskanen et al 2004). In a recent study, fenofibrate 
significantly reduced uric acid levels by 27.9% (from 
408 ± 72 μmol/L to 294 ± 84 μmol/L, p < 0.001) by inducing 
a profound increase in the fractional excretion of uric acid 
(from 8% ± 3% to 13% ± 4%, p < 0.01), independently of 
any change in lipid parameters (Liamis et al 1999; Elisaf 
et al 2002).
In some, but not all studies, fenofibrate has been found 
to improve insulin sensitivity and carbohydrate metabolism 
in patients with DM or impaired glucose tolerance (Guerre-
Millo et al 2000; Walus-Idzior et al 2000; Malik et al 2001; 
Elisaf 2002; Nagai et al 2002; Wysocki et al 2004; Koh, Han, 
Quon, et al 2005). It is possible that hypertriglyceridemia 
contributes to the induction of glucose intolerance and 
fibrates enhance insulin action by lowering TG (Steiner 
1991; Avogaro et al 1995; Marcus 2001; Elisaf 2002). 
Another possible explanation for this improvement in insulin 
sensitivity could be the induction of FFA-binding protein as 
well as the stimulation of β-oxidation in skeletal muscles 
(Furuhashi et al 2002). Interestingly, an important effect of 
treatment with fenofibrate on the progression of albuminuria 
has been recently reported in patients with DM (Ansquer 
et al 2005; Keech et al 2005), along with a favorable effect 
on the need for retinal laser therapy (Keech et al 2005). 
Fenofibrate also significantly increased plasma adiponectin 
levels in patients with primary hypertriglyceridemia or with 
combined hyperlipidemia (Koh, Han, Quon, et al 2005; Koh, 
Quo, Han, et al 2005).
A reduction in serum alkaline phosphatase (ALP) and 
gamma glutamyltranspeptidase (gGT) activity is a well-
documented effect of treatment with fenofibrate (Steinmetz et 
al 1981; Mikhailidis et al 1998; Genest et al 2004). Fenofibrate 
has been shown to reduce ALP activity by 14% (p < 0.00001), 
significantly more than gemfibrozil (p < 0.0001) (Ganotakis et 
al 2002). Interestingly, this decrease in serum ALP has been 
used to monitor compliance to fibrate treatment (Mikhailidis 
et al 1998; Genest et al 2004). Even though the underlying 
mechanisms explaining these results remain undefined, it 
has been speculated that changes in hepatic fat deposition 
may be involved; more specifically, the fenofibrate-induced, 
PPARα-mediated stimulation of oxidative metabolism of   
FFA in the liver might reduce the potential for lipid deposition 
in the liver cells (Mikhailidis et al 1998). This mechanism 
could also account for the smaller decrease in ALP with 
gemfibrozil, which does not activate PPARα (Post et al 2001). 
Alternatively, the decreased liver ALP release might result 
from a reduction in the rate of hepatic bile acid secretion (Day 
et al 1993). Fibrates suppress bile acid biosynthesis in rodents 
via PPARα-activation; among fibrates, gemfibrozil had the 
smallest effect (Post et al 2001; Roglans et al 2004).
Fenofibrate increases homocysteine in both the fasting 
and fed state (Dierkes et al 2001; Giral et al 2001; Stule et 
al 2001; Westphal et al 2001; Mayer et al 2003; Melenovsky 
et al 2003); gemfibrozil does not increase homocysteine, 
possibly due to different interaction with PPARα (Westphal 
et al 2001; Syvanne et al 2004). The addition of vitamin 
supplementation (folic acid and vitamins B6 and B12) can 
markedly reduce the homocysteine elevation induced by 
fenofibrate (Dierkes et al 2001; Stule et al 2001; Mayer et 
al 2003; Melenovsky et al 2003). Recently, an increase of 
the median plasma homocysteine concentration by about   
4 μmol/L has been reported with fenofibrate (Keech et al 
2005). Epidemiological data suggest an increase in risk 
of 10%–20% in cardiovascular events could be associated 
with this difference (HSC 2002), but whether changes 
in homocysteine are causal for cardiovascular disease or 
an epiphenomenon is unknown, and to date there is no 
randomized evidence that lowering homocysteine levels 
reduces cardiovascular disease events. Furthermore, 
fenofibrate induced a selective increase of protein-bound 
homocysteine in rodents, whereas the atherogenic reduced 
fraction of homocysteine remained unchanged (Legendre 
et al 2002). In addition, a recent analysis revealed that the 
fenofibrate-induced increase in homocysteine levels did 
not attenuate the beneficial effects of the drug on CHD 
progression or clinical events (Papadakis et al 1999).international Journal of Nanomedicine 2006:1(2) 136
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Fenofibrate increases creatinine plasma levels (Levin et al 
2000; Keech et al 2005), which is fully reversed within 6–8 
weeks of stopping fenofibrate (Keech et al 2005); however, 
permanent increases in serum creatinine levels have been 
rarely reported in renal transplant recipients (Broeders et al 
2000). Gemfibrozil does not appear to increase creatinine 
levels (Tsimihodimos et al 2001; Westphal et al 2001). One 
possible explanation for this effect is that activation of PPARα 
by fenofibrate downregulates the renal cyclooxygenase-2 
enzyme system and may impair the synthesis of vasodilating 
prostaglandins (de la Serna and Cadarso 1999). In contrast, 
gemfibrozil does not activate PPARs, which may account 
for the observed absence of an increase in serum creatinine 
(Yoshinari et al 1998). It has been proposed that fenofibrate 
increases the metabolic production rate of creatinine 
(Hottelart et al 2002). The fenofibrate-induced increase in 
creatinine plasma levels does not appear to be related to 
alterations in renal hemodynamics (Hottelart et al 1999, 
2002) or in tubular creatinine secretion (Hottelart et al 
2002); accelerated muscular cell lysis has also been ruled 
out (Hottelart et al 2002). It must be pointed out that this 
increase in creatinine plasma levels is not associated with 
reductions in glomerular filtration rate (Hottelart et al 1999, 
2002; Deighan et al 2001), and therefore seems unlikely to 
be clinically significant.
Other fibrates also display pleiotropic effects. Ciprofibrate 
has been shown to decrease CRP and fibrinogen and to 
increase fibrinolysis and attenuate platelet hyperaggregability 
(Simpson et al 1989; Rizos, Bairaktari, et al 2002; Rizos, 
Kostoula, et al 2002). Ciprofibrate also improves fasting and 
postprandial endothelial function and reduces postprandial 
oxidative stress in patients with DM (Evans et al 2000). 
Bezafibrate decreases CRP (Gomez-Gerique et al 2002), 
reverses insulin resistance (Taniguchi et al 2001), and 
increases exercise-induced coronary artery dilation in 
patients with CHD (Seiler et al 1995). It should be noted 
that bezafibrate is an unusual member of the
 fibrate class in 
that although it acts primarily as a PPARα agonist,
 it also 
has some effect on PPARδ (Peters et al 2003). Gemfibrozil 
reduces CRP (Despres et al 2003), lowers the factor 
VII–phospholipid complex, reduces plasma levels of PAI-1, 
improves fibrinolytic activity (Mussoni et al 2000) and, in 
patients with DM, improves insulin sensitivity and flow-
mediated vasodilation (Steiner 1991; Avogaro et al 2001). 
All fibrates significantly reduced serum ALP activity, with 
bezafibrate inducing the greatest changes and gemfibrozil 
the smallest (Ganotakis et al 2002). All fibrates, except 
gemfibrozil, reduce fibrinogen and increase homocysteine 
levels (Branchi et al 1993; Schonfeld 1994; Durrington et al 
1998; Chan and Chow 2001; Westphal et al 2001; Young and 
Woodside 2001; Maison et al 2002). On the other hand, all 
fibrates, with the possible exception of gemfibrozil, increase 
serum creatinine levels (Broeders et al 2000; Rizos, Kostoula, 
et al 2002).
Major clinical trials of fibrates
Fibrate treatment has been shown to slow the rate of 
atherosclerotic disease progression and reduced cardio-
vascular events in both primary and secondary prevention 
trials (NICE 2002). The Helsinki Heart Study (HHS) tested 
gemfibrozil 600 mg twice daily in 4081 men, aged 40–55 
years, with primary dyslipidemia (nonHDL-C > 5.17 mmol/
L) and without previous coronary disease, and demonstrated 
a significant 34% reduction in combined fatal and nonfatal 
myocardial infarction (MI) associated with gemfibrozil 
therapy (p < 0.02) (Frick et al 1987). The overall reduction in 
coronary events was greater than would have been expected 
on the basis of lowering of LDL-C alone and was 44% when 
baseline HDL-C was < 1.08 mmol/L and 58% when baseline 
TG levels were > 2.3 mmol/L (Manninen et al 1992; Koskinen 
et al 1992). Gemfibrozil lowered coronary events more in 
people with DM than in those without in a post-hoc analysis 
(3.4% vs 10.5%, respectively), though the difference was not 
significant due to the low number of diabetic patients in this 
study (n = 135) (Koskinen et al 1992).
The Bezafibrate Coronary Atherosclerosis Intervention 
Trial
 (BECAIT) (de Faire et al 1996) was a 5-year, placebo-
controlled study of bezafibrate 200 mg 3 times daily and 
dietary intervention in male survivors of MI below 45 years   
of age with dyslipidemia (predominantly hypertriglyceri-
demia). The angiographic analysis included 81 patients who 
underwent baseline and at least 1 post-treatment angiogram, 
at 2 and 5 years. Changes in mean minimum lumen diameter 
indicated that there was significantly less disease progression 
in focal lesions in the bezafibrate group than in the placebo 
group (p = 0.049). Parallel, but not significant, treatment 
effects were observed for mean segment diameter and 
percent stenosis. Three patients treated with bezafibrate and 
11 patients in the placebo group suffered coronary events 
during the course of the trial (p = 0.02).
The Lopid Coronary Angiography Trial (LOCAT) 
randomly assigned 395 postcoronary bypass men, who had 
a low HDL cholesterol (≤ 1.1 mmol/L) as their
 main lipid 
abnormality and LDL cholesterol ≤ 4.5 mmol/L, to receive 
gemfibrozil 1200 mg/day or placebo (Frick et al 1997). 
Coronary angiography was performed at baseline and after, international Journal of Nanomedicine 2006:1(2) 137
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on average, 32 months of therapy. The gemfibrozil group 
showed significantly smaller changes in per-patient means 
of average diameters of native coronary segments (p = 0.009) 
and in minimum luminal diameters of stenosis (p = 0.002) 
compared with the placebo group. In aortocoronary bypass 
grafts, fewer patients assigned to gemfibrozil had new lesions 
in the follow-up angiogram compared with subjects assigned 
to placebo (p < 0.001).
The Veterans Affairs High-Density Lipoprotein Choles-
terol Intervention trial (VA-HIT) was designed specifically 
to look at patients with low HDL-C (< 1.03 mmol/L) and 
included 2531 men with CHD. LDL-C levels, which were 
considered low in this population (mean, 2.87 mmol/L), 
did not change (Rubins et al 1999). After an average of 5.1 
years, gemfibrozil 1200 mg daily provided a significant 24% 
reduction in the composite end point of CHD death, nonfatal 
MI, or stroke, and reduced cardiovascular events, stroke, and 
CHD death by 24%, 25%, and 22% respectively (Rubins 
et al 1999). Subgroup analysis from this study highlighted 
the particular benefit of gemfibrozil among patients with 
concomitant DM (n = 769), in whom it reduced the risk of 
the composite end point by 32% and cardiovascular events, 
stroke, and CHD death by 32%, 40%, and 41% respectively 
(Rubins et al 2002). Interestingly, despite the greater efficacy 
of gemfibrozil in reducing the risk of CVD recurrence in 
patients with DM, the increase in HDL-C levels and the 
reduction in TG levels were less pronounced among these 
patients (Rubins et al 2002).
The Bezafibrate Infarct Prevention (BIP) trial tested the 
effect of bezafibrate 400 mg daily in 3090 patients with CHD, 
low HDL-C levels, and moderately elevated LDL-C levels 
(mean, 3.88 mmol/L) (The BIP study group 2000). Although 
the CHD event reduction was small (7%) and not significant 
in this trial (The BIP study group 2000), posthoc analyses 
suggested a preferential benefit of CHD risk reduction of 
39% (p = 0.02) in the subgroup of patients with TG levels 
≥ 2.25 mmol/L or with the metabolic syndrome (MetS) 
(Tenenbaum et al 2005).
In the Saint Mary’s, Ealing, Northwick Park Diabetes 
Cardiovascular Disease Prevention (SENDCAP) study 
(Elkeles et al 1998), 164 patients with DM and without 
previous cardiovascular disease were randomized
 to 
bezafibrate or placebo. Although there was no significant 
difference between groups
 in the progression of ultrasonically 
measured arterial disease in carotids and femoral arteries at 3 
years, those treated with bezafibrate experienced a significant 
reduction
 in the combined incidence of probable ischemic 
change on resting
 electrocardiogram and documented MI.
In the Diabetes Atherosclerosis Intervention Study 
(DAIS) (DAIS Investigators 2001), of 418 patients with DM 
and good glycemic control, mild lipoprotein abnormalities
 
typical of DM, and with angiographically documented CHD 
(half patients had no previous clinical CHD), fenofibrate 
200 mg/day was associated with a significantly smaller 
increase in percentage diameter stenosis than the placebo 
group (p = 0.02), a significantly smaller decrease in minimum 
lumen diameter (p = 0.029), and a nonsignificantly smaller 
decrease in mean segment diameter (p = 0.171) over 3 years. 
There were also fewer clinical events with treatment (38 in 
the fenofibrate group vs 50 in the placebo group, 23% risk 
reduction), but this finding was not significant and the study 
was not designed to examine clinical outcomes.
The Lower Extremity Arterial Disease Event Reduction 
(LEADER) study looked at the effect of bezafibrate 400 mg 
daily in 1568 men, with a mean age of 68 years, with lower 
extremity arterial disease (Meade et al 2002). Although 
this study showed no benefit on CHD events or stroke, 
there was a 19% reduction in MI over 4.6 years and a 62% 
reduction in CHD in the subgroup of men aged < 65 years. 
An improvement in patients’ symptoms was also noted.
Finally, the Fenofibrate Intervention and Event Lowering 
in Diabetes (FIELD) study was a multinational, randomized, 
controlled trial that enrolled 9795 participants with DM, 
aged 50–75 years; 2131 patients had previous cardiovascular 
disease and 7664 did not (Keech et al 2005). Patients received 
fenofibrate daily or matching placebo and were followed up 
for a median of 5 years. 5.9% (n = 288) of patients on placebo 
and 5.2% (n = 256) of those on fenofibrate had a coronary 
event (relative reduction of 11%, p = 0.16). This finding 
corresponds to a significant 24% reduction in nonfatal MI 
(p = 0.01) and a nonsignificant increase in CHD mortality. 
Total cardiovascular disease events were significantly reduced 
by 11% (p = 0.035). This finding included a 21% reduction 
in coronary revascularization (p = 0.003). Total mortality 
was 6.6% in the placebo group and 7.3% in the fenofibrate 
group (p = 0.18). The effects of fenofibrate on cardiovascular 
events were less than planned for in the study design. Of note, 
more patients allocated placebo (17%) than fenofibrate (8%; 
p < 0.0001) commenced other lipid treatments, predominantly 
statins, and this might have masked a moderately larger 
treatment benefit. A second possible explanation for the small 
effect of fenofibrate on cardiovascular events in the FIELD 
study relates to the unexpectedly small difference in HDL-C 
concentrations between the two groups (1.2% increase in the 
fenofibrate group compared to the placebo group). It is well 
known that treatment with fibrates in patients with diabetes, international Journal of Nanomedicine 2006:1(2) 138
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as those in the FIELD study, results in smaller increases in 
HDL-C levels than in the nondiabetic population (DAIS 
Investigators 2001; Rubins et al 2002). In addition, the 
initiation of other lipid-lowering medications during the study 
further decreased the differences in HDL-C levels between 
study groups (0.5% increase in patients who started other 
lipid treatments vs 2.1% in those who did not). However, 
the initial increase in HDL-C levels (5.1% at 4 months) also 
decreased (to 2.1% at study end) in patients who did not 
start other lipid treatments, while the effect of fenofibrate 
on other lipid fractions remained stable; the explanation for 
this finding is unclear.
Even though the results of VA-HIT and BIP studies appear 
to be contradictory, it must be mentioned that the mean 
LDL-C value in VA-HIT was lower than that in BIP (2.89 vs 
3.82 mmol/L) (Rubins et al 1999; The BIP study group 2000). 
Furthermore, it has already been mentioned that a subgroup 
of patients in BIP, with HDL-C and TG levels similar to the 
VA-HIT population, had a statistically significant reduction in 
cardiovascular risk (Tenenbaum et al 2005). This comparative 
analysis of the VA-HIT and BIP studies shows that treatment 
with fibrates might be more beneficial in reducing the risk of 
vascular events in patients with elevated TG levels and low 
HDL-C levels, but with LDL-C levels close to the target levels 
for secondary prevention of CVD (< 2.6 mmol/L) (Rizos and 
Mikhailidis 2002).
Finally, the evidence from HHS (Koskinen et al 1992), 
VA-HIT (Rubins et al 2002), and BIP (Tenenbaum et al 
2005) suggests possible larger-than-average benefits of 
fibrate therapy in patients with DM or the MetS than in those 
without; in contrast, this was not observed in the FIELD 
study (Keech et al 2005). Moreover, the reduction in CHD 
events noted in the latter study was less than that reported 
in other randomized trials of fibrate therapy, particularly in 
patients with diabetes and low HDL-C in the VA-HIT trial 
(Rubins et al 2002) or with MetS in a post-hoc analysis of 
the BIP trial (Tenenbaum et al 2005). However, VA-HIT and 
BIP were both secondary prevention studies with different 




The different mechanisms of action of fibrates and statins 
provide a rationale for combination drug therapy in high-
risk patients with combined hyperlipidemia refractory 
to monotherapy. However, fibrate–statin combination is 
associated with a 1%–5% risk of myopathy, which may 
occasionally be accompanied by rhabdomyolysis and renal 
failure (Miller and Spence 1998; Guay 1999; Mantel-
Teeuwisse et al 2002; NCEP 2002; Pasternak et al 2002; 
Taher et al 2002; Thompson et al 2003). Risk factors include 
underlying renal or hepatic insufficiency, age greater than 
70 years, debilitation, high doses of statins, and multiple 
medications (Guay 1999). Gemfibrozil appears to account for 
most cases of severe myopathy and rhabdomyolysis; during
 
a survey in 1998–2002 on total reports of rhabdomyolysis
 in 
patients on fibrate–statin combination therapy, gemfibrozil–
cerivastatin accounted for most reports
 (88%), whereas 
fenofibrate–cerivastatin
 was associated with a small 
proportion of cases (2.3%) (Jones and Davidson 2005).   
Indeed, no significant side-effects were observed when 
fenofibrate was co-administered with a variety of statins 
(Athyros et al 2002a, 2002b; Taher et al 2002; Vega et al 2003; 
Keech et al 2005; Koh, Ahn, Jin, et al 2005; Grundy et al   
2005). The exact mechanism of this interaction and the 
subsequent myotoxicity is unknown; statins may cause 
muscle toxicity on their own (NCEP 2002; Pasternak et al 
2002; Thompson et al 2003). In vitro studies have highlighted
 
that gemfibrozil may increase the myotoxic effects of statins 
(Prueksaritanont, Tang, 2002; Prueksaritanont, Zhao, et al 
2002). In addition, coadministration
 of gemfibrozil led to 
significant increases in systemic exposure to several statins, 
including pravastatin (increased by 202%) (Kyrklund et 
al 2003), simvastatin (by 185%) (Backman et al 2000),   
lovastatin (by 280%) (Kyrklund et al 2001), and cerivastatin 
(by 559%) (Backman et al 2002).
 Recent in vitro microsomal 
studies suggest that the
 observed statin–gemfibrozil 
interaction is due to inhibition
 of statin acid glucuronidation 
by gemfibrozil (Prueksaritanont, Tang, et al 2002; 
Prueksaritanont, Zhao, et al 2002). Moreover, gemfibrozil 
reduces the renal clearance of pravastatin and, possibly, 
inhibits
 an organic anion-transporting polypeptide or some 
other transporter of pravastatin (Kyrklund et al 2003). In 
contrast, fenofibrate does not have any significant effects on 
the pharmacokinetics of pravastatin (Gustavson et al 2005) 
or simvastatin (Bergman et al 2004). Furthermore, in vivo 
data suggest that fenofibric acid does not undergo significant 
oxidative metabolism by cytochrome P450 and does not 
inhibit most cytochrome P450 isoforms (Keating and Ormrod 
2002; Telford and Elisaf 2003).
Fibrate–statin combination treatment has been shown 
to lead to greater changes in lipid levels compared with 
monotherapy (Athyros et al 1997, 2002a, 2002b; Ellen and 
McPherson 1998; Kiortsis et al 2000; Taher et al 2002;   
Vega et al 2003; Grundy et al 2005; Keech et al 2005;   international Journal of Nanomedicine 2006:1(2) 139
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Koh, Ahn, Jin, et al 2005). In one of these studies, 120 
consecutive patients were randomly assigned to atorvastatin 
20 mg/day (n = 40), fenofibrate 200 mg/day (n = 40), or a 
combination of both (n = 40) (Athyros et al 2002a). After 24 
weeks, the atorvastatin–fenofibrate combination reduced 
total cholesterol (TC) by 37%, LDL-C by 46%, and TG by 
50%, whereas it increased HDL-C by 22% (p < 0.0001 for 
all), significantly better than those of both monotherapies. 
Of the patients on drug combination, 97.5% reached the 
LDL-C treatment goal of < 2.59 mmol/L, 100% reached the 
desirable TG levels of < 2.25 mmol/L, and 60% reached the 
optimal HDL-C levels of > 1.16 mmol/L; these rates were 
also significantly higher than those of both monotherapies. 
No significant adverse events were recorded. All patients 
remained under the 3-fold level of the upper
 normal limit of 
serum transaminase values and no patient presented myalgia 
or creatine kinase levels > 10-fold from pretreatment values. 
In another prospective, randomized trial, 300 nondiabetic 
patients with MetS were randomly allocated to atorvastatin 
20 mg/day (n = 100), fenofibrate 200 mg/day (n = 100), or both 
drugs (n = 100) (Athyros et al 2005). After 12 months, the 
combined treatment group attained lipid targets to a greater 
extent than those in the monotherapy groups. In the most 
recent study, combination therapy with simvastatin 20 mg/
day plus fenofibrate 160 mg/day (n = 411) was compared 
with monotherapy with simvastatin 20 mg/day (n = 207) in 
patients with combined hyperlipidemia (Grundy et al 2005). 
From baseline to week 12, median TG levels decreased 
43.0% and 20.1% (treatment difference −23.6%, p  < 0.001), 
mean LDL-C levels decreased 31.2% and 25.8% (treatment 
difference −5.4%, p < 0.001), and HDL-C levels increased 
18.6% and 9.7% (treatment difference 8.8%, p < 0.001) 
in the combination therapy versus monotherapy groups, 
respectively. No patient experienced clinical myopathy or 
severe abnormalities in liver function. Despite these emerging 
data, there are still no currently published trials of surrogate 
atherosclerosis end points or hard outcomes using a statin–
fibrate combination compared with either a statin alone or a 
fibrate alone (NCEP 2002; ADA 2004). Short-term studies 
suggest that the combination of a statin and fibrate can reduce 
CHD risk status significantly more than each drug alone in 
patients with DM (Athyros et al 2002a). Long-term follow-up 
data from 525 patients with combined hyperlipidemia who 
were treated with 4 different statin–fibrate combinations 
showed that total and CHD mortality, as well as morbidity 
and need for revascularization, were much better than 
those of the landmark studies with statins in patients with 
hypercholesterolemia, both in secondary and primary CHD 
prevention; however, this was not a placebo-controlled 
trial and its size lacked the statistical power of a survival 
study (Athyros et al 2001). A 6-year prospective primary 
intervention study, the Lipids in Diabetes Study (LDS), 
involving 5000 patients with DM was underway comparing 
the effects of cerivastatin or fenofibrate monotherapy or 
combination therapy on CVD mortality and morbidity (Neil 
et al 2003). However, the study ended prematurely when 
cerivastatin was withdrawn in August 2001. The Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) 
study began in 2003 and is investigating the use of statin 
monotherapy or combination therapy with a fibrate as part of a 
wider intensive strategy to improve cardiovascular outcomes 
that also involves tight glycemic control and antihypertensive 
treatment (ACCORD 2005). It is expected to involve a total 
of 10 000 patients and is due to be completed by 2009. The 
American Heart Association and the American College 
of Cardiology recently released a joint clinical advisory 
reinforcing the benefits of combination therapy when used in 
selected cases in conjunction with careful patient monitoring, 
but suggested caution in groups of patients at higher risk 
of myopathy (Pasternak et al 2002). In addition, both the 
American Diabetes Association (ADA 2003) and the National 
Institute of Clinical Excellence of Great Britain (NICE 2002) 
guidelines recommend the appropriate use of statin–fibrate 
combination therapy.
Ezetimibe prevents
 the absorption of dietary and biliary 
cholesterol and reduces LDL-C by 15%–25% with modest 
favorable
 effects on TG and HDL-C in patients with primary 
hypercholesterolemia (van Heek et al 1997; Bays et al 
2001; Dujovne et al 2002; Knopp et al 2003). In a recent 
multicenter, randomized, double-blind,
 placebo-controlled, 
parallel-arm trial, 625 patients with mixed
 hyperlipidemia 
were randomized in a 1:3:3:3
 ratio to 1 of 4 daily treatments: 
placebo;
 ezetimibe 10 mg; fenofibrate 160 mg; fenofibrate 
160 mg plus ezetimibe 10 mg (Farnier et al 2005). After 
12 weeks, combination therapy reduced LDL-C and   
nonHDL-C significantly more than both monotherapies 
(p < 0.001) and was well tolerated. Thus, concomitant 
treatment with fibrates and ezetimibe may provide a 
complementary and alternative
 treatment for mixed 
hyperlipidemia without the safety
 concerns associated with 
co-administration of fibrates and statins.
Finally, in patients with mixed hyperlipidemia, the 
addition of colesevelam (a specifically engineered bile acid 
sequestrant) 3.75 g/day to fenofibrate 160 mg/day signifi-
cantly reduced LDL-C, nonHDL-C, TC, and apoB levels 
compared with fenofibrate monotherapy (McKenney et al international Journal of Nanomedicine 2006:1(2) 140
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2005). Fenofibrate–colesevelam combination therapy might 
also represent a safe, useful alternative for the treatment of 
mixed hyperlipidemia.
Fenofibrate in human 
immunodeficiency virus infection-
associated dyslipidemia
Fenofibrate has been assessed in patients with human 
immunodeficiency virus (HIV) infection-associated 
dyslipidemia, which is characterized by elevated concentra-
tions of TG, decreased levels of HDL-C, and altered 
distribution of LDL-C subfractions towards smaller particles 
(Grunfeld et al 1992; Stein et al 2001; Badiou et al 2003). 
This disorder is mainly attributed to the use of protease 
inhibitors (Carr et al 1998), even though several studies 
indicate that disturbances in lipoprotein metabolism in 
HIV-infected patients exist even before the initiation of 
antiretroviral therapy (Grunfeld et al 1992). Fenofibrate 
represents a safe and effective therapeutic option in these 
patients (Calza et al 2002, 2003; Badiou et al 2004; and 
may act synergistically with antiretroviral therapy, since it 
was shown that activation of PPARα receptors may result in 
inhibition of HIV replication (Skolnik et al 2002).
Guidelines
The Adult Treatment Panel III (ATP III) of the National 
Cholesterol Education Program (NCEP) recognized that a 
substantial proportion of patients have mixed dyslipidemia, 
which is characterized by increased levels of TG, TG-rich 
lipoprotein remnants and apoB, small dense LDL particles, 
low HDL-C levels, and is associated with substantial 
elevation in cardiovascular event risk (NCEP 2002). Mixed 
dyslipidemia is closely related to insulin resistance and 
patients with DM, as well as those with the MetS, often 
demonstrate this lipid profile (Wilson et al 1985; Assmann 
and Schulte 1988; Feingold et al 1992; Guerin et al 2001; 
Farnier and Picard 2001; Haffner 2002; Taskinen 2003). The 
MetS represents a cluster of metabolic abnormalities driven 
by abdominal obesity and insulin resistance, leading to the 
development of high blood pressure, mixed dyslipidemia, 
as well as impairment of glucose tolerance (NCEP 2002). 
In an analysis of 8814 US adults from the Third National 
Health and Nutrition Examination Survey, the prevalence 
of the MetS was estimated to be 24% (Ford et al 2002); the 
European Group for the Study of Insulin Resistance suggests 
a similar prevalence in Europe (Balkau et al 2002). MetS 
confers an increased risk of CVD-related morbidity and 
mortality (Isomaa et al 2001; Lakka et al 2002; Girman 
et al 2004; Athyros et al 2004b) and all-cause mortality 
(Lakka et al 2002; Grundy, Brewer, et al 2004). The effect of 
clustering of MetS components on
 the risk of CHD morbidity 
in individuals with the MetS appears greater than the relative 
risk associated with
 its individual components (Isomaa et al 
2001; Athyros et al 2004b).
The ATP III guidelines currently recommend a stepped-
care approach to patients with mixed dyslipidemia (NCEP 
2002). LDL-C levels remain the primary target of therapy 
and statins are the mainstay of therapy in patients with high 
levels of LDL-C. Once the LDL-C target has been reached, 
if the TG level is > 2.25 mmol/L, the secondary target is the 
nonHDL-C level. Goals for nonHDL-C are 0.77 mmol/L 
higher than goals for LDL-C. To this end, combination 
therapy is frequently required for mixed dyslipidemia.
Conclusions
Although the evidence base to support fibrate therapy is not 
as strong as that for statins, fibrates may have an adjunctive 
role in the treatment of patients with low HDL-C and 
high TG, especially in combination with statins (Grundy, 
Cleeman, et al 2004). Treatment with fibrates also appears 
to be particularly appropriate in patients with a high risk of 
CHD but no or little increase in LDL-C levels (Sacks 2002). 
A HDL-C treatment target of >1.0mmol/L is recommended 
in patients with low HDL-C who are currently receiving 
statins according to clinical guidelines, as well as those who 
are not (Sacks 2002).
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